A 35-Year-Old Woman Presenting With Life-Threatening Fulminant Myocarditis After COVID-19: A Case Report.

Am J Case RepSep 14, 2026 (epub)
Case ReportCardiologyEmergency Medicine

Darejan Mdinaradze, Ia Barabadze, Nikoloz Natsvlishvili

✦ AI-curated · Sources linked

Case in brief

A 35-year-old previously healthy woman presented to the emergency department with severe chest pain, dyspnea, and cardiogenic shock following COVID-19. Initial tests revealed elevated cardiac biomarkers and ECG abnormalities, while coronary angiography ruled out acute occlusion. Despite transient improvement with inotropic support, she rapidly deteriorated, experiencing polymorphic ventricular tachycardia that progressed to cardiac arrest and death, consistent with fulminant myocarditis.

Diagnostic / clinical pearl

Clinicians should be aware that fulminant myocarditis can occur rapidly in previously healthy individuals post-COVID-19, necessitating prompt recognition and aggressive supportive care.

Source

PubMed · PMID 42735205

Published in Am J Case Rep. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Cardiology

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.